Evidence map›Paper›PMID 41568999›Full record

ArticleOtolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery2026

Exploration of Therapeutic Targets Using CDK4 Inhibitors for Head and Neck Mucosal Melanoma.

Takayoshi Hattori, Makiko Fujii, Tsutomu Ueda, Akira Ishikawa, Yuichi Mine, Bingwen Xu, Tomoya Suehiro, Minoru Hattori, Hiroaki Tahara, Yuki Sato and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Takayoshi HattoriDepartment of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID https://orcid.org/0009-0008-6568-6855
Makiko FujiiDepartment of Genomic Oncology, Oral Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Tsutomu UedaDepartment of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID https://orcid.org/0000-0001-9771-3880
Akira IshikawaDepartment of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID https://orcid.org/0000-0002-1528-1939
Yuichi MineDepartment of Medical Systems Engineering, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID https://orcid.org/0000-0002-7057-1955
Bingwen XuDepartment of Genomic Oncology, Oral Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Tomoya SuehiroDepartment of Genomic Oncology, Oral Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Minoru HattoriDepartment of Medical Education Institute of Biomedical & Health Sciences, Center for Medical Education Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID https://orcid.org/0000-0002-7478-0033
Hiroaki TaharaDepartment of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Yuki SatoDepartment of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Nobuyuki ChikuieDepartment of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Takayuki TaruyaDepartment of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Takao HamamotoDepartment of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Takashi IshinoDepartment of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID https://orcid.org/0000-0002-0646-0839
Sachio TakenoDepartment of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID https://orcid.org/0000-0002-9853-2501

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveMucosal melanoma (MM) is an extremely aggressive malignant tumor in the head and neck region associated with a poor prognosis. In the present study, we conducted cell proliferation assay and western blotting using cell lines derived from MM and the immunohistochemical analysis of pathological MM tissues to identify novel therapeutic targets. Herein, we report on the potential of cyclin-dependent kinase 4 (CDK4) inhibitors as molecular targeted therapies for MM. STUDY

designRetrospective cohort study and laboratory analysis.

settingA tertiary referral center.

methodsMTT assay and western blotting were performed on the HMV-II (RCB0777) and GAK (JCRB0180) cell lines, treated with the CDK4 inhibitors abemaciclib (LY2835219) and palbociclib (PD-0332991). This retrospective cohort study included patients with head and neck MM; immunohistochemistry was performed on clinical specimens.

resultsAbemaciclib and palbociclib showed concentration-dependent cytostatic effects on HMV-II and GAK cells at 72 hours in the MTT assay. In western blotting, they exhibited concentration-dependent inhibitory effects on phosphorylated RB1 in HMV-II and GAK cells at 24 hours. Of 23 patients, 18 (78.3%) had positive results on CDK4 immunostaining. No clinicopathologic factors were significantly associated with CDK4 status.

conclusionAbemaciclib and palbociclib may suppress MM cell proliferation. The CDK4 signaling pathway is a potential target for molecular-targeted therapies in MM.

Indexed as

AminopyridinesBenzimidazolesCyclin-Dependent Kinase 4Head and Neck NeoplasmsMelanomaPiperazinesPyridinesAgedBlotting, WesternCell Line, TumorCell ProliferationFemaleHumansImmunohistochemistryMaleMiddle AgedabemaciclibAminopyridinesBenzimidazolesCDK4 protein, humanCyclin-Dependent Kinase 4palbociclibPiperazinesPyridinescell linecyclin‐dependent kinase 4growth inhibitorshead and neckmolecular‐targeted therapymucosal melanoma

Identifiers

PMID41568999
PMCPMC12948400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.